Effects of Treatment with PCSK9 Inhibitors
| LDL-C reduction | Treatment with evolocumab or alirocumab results in approximately 55% or 53% reduction in LDL-C levels, respectively. |
| Effect on lipid panel | Evolocumab and alirocumab results in 7.6% and 8% increases in HDL-C, respectively. There was reduction in non-HDL-C, total cholesterol, triglycerides, and lipoprotein(a) levels. |
| Effect on clinical outcomes | PCSK9 inhibitor results in 15% to 48% lower hazard of a composite of CV death, MI, stroke, hospitalization for UA, or coronary revascularization (1.5% absolute reduction of events) compared with standard medical therapy. Long-term outcome data are not available. |
| Plaque regression | Significantly more plaque volume reduction seen with PCSK9 inhibitor treatment as compared with statin therapy. |
PCSK9, proprotein convertase subtilisin/kexin type 9; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; CV, cardiovascular; MI, myocardial infarction; UA, unstable angina.